C-BIOMEX Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $5.13M

  • Investors
  • 11

C-BIOMEX General Information

Description

Developer of therapies based on theranostic technology designed to treat cancer, aging-related, and inflammatory diseases. The company's proprietary technologies can simultaneously diagnose and treat diseases like renal cell carcinoma, solid tumors, prostate cancer, and neuroendocrine cancer, enabling clients to overcome the limitations of existing kidney cancer diagnosis and treatment.

Contact Information

Website
www.cbiomex.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 615.87
  • Cheongam-ro, Nam-gu, Jigok-dong
  • Pohang, Gyeongsangbuk 37673
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Number 615.87
  • Cheongam-ro, Nam-gu, Jigok-dong
  • Pohang, Gyeongsangbuk 37673
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

C-BIOMEX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 21-Jun-2022 $5.13M Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 25-Mar-2020 Completed Clinical Trials - General
4. Seed Round 01-Dec-2018 Completed Clinical Trials - General
3. Accelerator/Incubator 30-Apr-2018 Completed Clinical Trials - General
2. Seed Round 20-Dec-2017 Completed Clinical Trials - General
1. Accelerator/Incubator Completed Clinical Trials - General
To view C-BIOMEX’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

C-BIOMEX Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

C-BIOMEX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026160729-A1 Peptide constructs targeting carbonic anhydrase ix and use thereof Pending 21-Jan-2025
WO-2026095735-A1 Peptide construct targeting fibroblast activation protein-α (fap-α) and use thereof Pending 04-Nov-2024
AU-2024298898-A1 Peptide structure targeting carbonic dehydrogenase ix and use thereof Pending 25-Jul-2023
EP-4752154-A1 Peptide structure targeting carbonic dehydrogenase ix and use thereof Pending 25-Jul-2023
US-20260137821-A1 Peptide structure targeting carbonic dehydrogenase ix and use thereof Pending 25-Jul-2023 C07K1/1077
To view C-BIOMEX’s complete patent history, request access »

C-BIOMEX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

C-BIOMEX Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Enlight Ventures Venture Capital Minority
E&Venture Partners Venture Capital Minority
Mirae Asset Venture Investment Venture Capital Minority
Pureun Investment Venture Capital Minority
Starset Investment Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

C-BIOMEX FAQs

  • When was C-BIOMEX founded?

    C-BIOMEX was founded in 2017.

  • Where is C-BIOMEX headquartered?

    C-BIOMEX is headquartered in Pohang, South Korea.

  • What is the size of C-BIOMEX?

    C-BIOMEX has 11 total employees.

  • What industry is C-BIOMEX in?

    C-BIOMEX’s primary industry is Biotechnology.

  • Is C-BIOMEX a private or public company?

    C-BIOMEX is a Private company.

  • What is C-BIOMEX’s current revenue?

    The current revenue for C-BIOMEX is .

  • How much funding has C-BIOMEX raised over time?

    C-BIOMEX has raised $7.6M.

  • Who are C-BIOMEX’s investors?

    Enlight Ventures, E&Venture Partners, Mirae Asset Venture Investment, Pureun Investment, and Starset Investment are 5 of 11 investors who have invested in C-BIOMEX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process